Regeneron Pharmaceuticals (NASDAQ:REGN) is a leading biopharmaceutical company headquartered in Tarrytown, New York. Since its founding in 1988 by Dr. Leonard Schleifer and Dr. George Yancopoulos, Regeneron has focused on the discovery, development and commercialization of medicines for the treatment of serious medical conditions. The company applies its proprietary VelociSuite® technologies to accelerate the identification of therapeutic antibodies and small molecules across a range of disease areas.
Regeneron’s commercial portfolio includes EYLEA® (aflibercept) for multiple retinal diseases, Dupixent® (dupilumab) for atopic dermatitis and other type 2 inflammatory disorders, Libtayo® (cemiplimab) for certain cancers, and Inmazeb® (atoltivimab, maftivimab and odesivimab-ebgn) for the treatment of Ebola virus infection. In addition to its marketed products, the company maintains a broad clinical pipeline targeting cardiovascular, metabolic, ophthalmic, oncology and rare diseases, leveraging partnerships with industry leaders and academic institutions.
With a global reach, Regeneron’s research, manufacturing and commercial operations extend across North America, Europe and selected international markets. The company’s integrated manufacturing facilities in New York support both clinical and commercial supply, while its international collaborations ensure regulatory approvals and distribution in key regions.
Leadership at Regeneron remains anchored by co-founder and Chief Executive Officer Dr. Leonard Schleifer and co-founder and Chief Scientific Officer Dr. George Yancopoulos, whose collaborative vision has driven the firm’s scientific innovations and strategic growth. Under their guidance, Regeneron continues to invest in cutting-edge research platforms and strategic alliances to address unmet medical needs worldwide.
